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Abstract
Background: Biomarker discovery studies often claim ‘promising’ findings,
motivating further studies and marketing as medical tests. Unfortunately, the patient
benefits promised are often inadequately explained to guide further evaluation and
few biomarkers have translated to improved patient care. We present a practical
guide for setting minimum clinical performance specifications to strengthen clinical
performance study design and interpretation.

Methods: We developed a step-by-step approach using test evaluation and
decision-analytic frameworks and present with illustrative examples.

Results: We define clinical performance specifications as a set of criteria that
quantify the clinical performance a new test must attain to allow better health
outcomes than current practice. We classify the proposed patient benefits of a new
test into three broad groups and describe how to set minimum clinical performance
at the level where the potential harm of false-positive and false-negative results do
not outweigh the benefits. (1) For add-on tests proposed to improve disease
outcomes by improving detection; define an acceptable trade-off for false-positive
versus true-positive results; (2) for triage tests proposed to reduce unnecessary tests
and treatment by ruling out disease; define an acceptable risk of false-negatives as a
safety threshold; (3) for replacement tests proposed to provide other benefits, or
reduce costs, without compromising accuracy, use existing tests to benchmark
minimum accuracy levels.

5

Conclusions: Researchers can follow these guidelines to focus their study
objectives and to define statistical hypotheses and sample size requirements. This
way, clinical performance studies will allow conclusions about whether test
performance is sufficient for intended use.

6

Introduction
Discovery of a ‘promising’ biomarker is common rhetoric in biomarker research with
claims of clinically important findings,1 but few discoveries progress to appropriate
clinical evaluation.2 Unfortunately, what is promised in terms of clinical performance
and patient benefits is often inadequately explained to guide further evaluation. An
audit of diagnostic test accuracy studies has documented that few state an explicit
hypothesis about the accuracy level that would favour clinical uptake, and
researchers frequently over-interpret the results.3 Such unwarranted optimism can
motivate subsequent futile studies, wasting research resources. Moreover, it can
lead to marketing of biomarkers as medical tests with no clinical benefits for patients
or the potential for harm.4

To date, discussion of failed clinical translation of biomarkers has primarily focused
on poor study design and inadequate validation of findings.5,
available to help address these problems.7-9

6

Guidelines are

However, these guidelines do not

include advice about determining whether biomarker performance is promising
enough to justify further evaluation as a medical test. For some gaps, modest test
accuracy will be sufficient to deliver clinical benefits for patients; for others, nearperfect accuracy will be required. Thus, for each potential test application, a critical
question is: what level of performance is sufficient? Biomarkers performing above
this level can be prioritised for further research. Poor performers can be considered
futile and discarded early.

7

A “go/no-go” threshold approach is routinely used for drug development, where a
new drug only progresses to a phase 3 randomised controlled trial if it meets prespecified minimum levels of safety and efficacy in a phase 2 study.10 It has also been
proposed for biomarker development by using a decision-analytic framework to set
minimum accuracy levels.11, 12 However, the concepts are not yet well understood by
non-statisticians and it is not commonly used, nor required by regulatory agencies for
pre-market approval of new tests. So far, regulatory agencies, such as the Food and
Drug Administration (FDA) in the United States and the Conformité Européene (CE)
marking body in the European Union (EU) require that new biomarkers meet
analytical performance specifications, and it has been possible to market tests based
on safety with limited clinical evidence. However, this situation is changing with
recent in vitro diagnostic (IVD) devices directives requiring more evidence on clinical
performance for intended use.13

To address this problem, members of the European Federation of Clinical Chemistry
and Laboratory Medicine’s Test Evaluation Working Group have developed a stepby-step guide on the practical aspects of setting clinical performance specifications
from a clinical decision-making perspective.

Methods
Definition and approach
We define clinical performance specifications as a set of criteria that quantify the
clinical performance a new test must attain to allow better health outcomes than
current practice.
8

We used established test evaluation and decision analysis frameworks to develop
the guide and piloted it on examples at three face-to-face meetings. Explanations of
the concepts and approach were refined at two training workshops attended by
clinicians, laboratory scientists, IVD industry, health economists, health technology
assessment and government re-imbursement agencies.

Test evaluation framework
To justify implementation as a medical test, a biomarker must lead to improved
health outcomes, or provide other benefits over existing tests without compromising
health outcomes, such as greater patient convenience, simplifying the health care
process, or reducing resource use.7

After discovery of an association between the biomarker and a clinical condition or
state, sometimes referred to as evidence of ‘scientific validity’,14 the five components
for evaluation as a medical test are: analytical performance – the technical ability of
the test assay/device to measure the biomarker, sometimes referred to as ‘analytical
validity’; clinical performance – the ability to provide information about the condition
or state of interest for its intended use in the relevant population, sometimes referred
to as ‘clinical validity’; clinical effectiveness – the ability to improve health outcomes
over existing tests; cost-effectiveness; and broader impact of use including societal
consequences.7

9

The initial focus for an evaluation is analytical and clinical performance as required
for regulatory approval. Both have an impact on clinical effectiveness, but good
analytical and clinical performance do not of themselves mean that the test will lead
to improved patient outcomes. By pre-specifying the minimum clinical performance
levels needed to achieve the proposed clinical benefits, researchers can design
more purposeful clinical performance studies to determine if test performance is
sufficient for intended use.

Measures of clinical performance include test accuracy which is traditionally
expressed as sensitivity and specificity; and by estimating the positive predictive
value (PPV) of a positive test result and negative predictive value (NPV) of a
negative test result (Supplementary Figure). PPV and NPV vary across populations
with different disease prevalence. Sensitivity and specificity can also vary between
populations due to differences in patient spectrum.15, 16 Thus, to provide meaningful
estimates of clinical performance, studies of test accuracy need to be conducted in a
population and in a well-defined clinical pathway that closely reflects how the test is
intended to be used in practice.

Decision-analytic framework
Taking a clinical decision-making perspective, the minimum acceptable clinical
performance for a test represents the accuracy level above which the intended
clinical benefits outweigh the potential harms.12 Fundamental to this approach is that
patients have to benefit from testing, and that testing primarily affects patient-
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important health outcomes through the way test results and findings are used to
guide downstream clinical actions.

To draw the link between test accuracy and health outcomes, one must define the
clinical consequences of true/false positive and negative results for the target
condition, relative to current practice without the new test. These are the clinical
decisions (actions) triggered by the test result and potential consequences for patient
health outcomes. In broad terms, a new test that detects more true positives (TP)
than existing tests may improve disease outcomes by allowing improved treatment
for individuals with a positive result; but may also detect more false positives (FP)
leading to iatrogenic harm through unnecessary further testing or treatment. We
define a FP as a finding that is subsequently confirmed to be incorrect; to distinguish
it from over-diagnosis, a pathologically ‘correct’ TP that does not represent clinically
significant disease.

Conversely, a test that detects more true negatives (TN) may reduce iatrogenic harm
by allowing avoidance of further tests or unnecessary treatment for individuals with a
negative result; but may also detect more false negatives (FN) leading to worse
disease outcomes through the missed opportunity for treatment.

Our guide is based on the decision-analytic principles described by Vickers et al.
who has expressed the trade-off between benefit and harm of a test as the ‘net
benefit’ (benefit – harm).17, 18 In its simplest form, the net benefit can be calculated as
(TP/N – FP/N), where N=number tested. It relies on the assumption that a TP leads
11

to health benefits, and requires the health consequences of TP and FP to be judged
on the same metric. This can be done by defining the number of FP that would be
tolerated to identify one TP (‘FP:TP threshold’) and weighting the FP/N proportion
accordingly, so the unit of net benefit is one TP.18 By definition, a test that exceeds
the minimum acceptable clinical performance levels achieves a net benefit >0. The
net benefit does not provide an estimate of the actual health consequences of a TP
finding e.g. longer survival time.

Results
Practical guide
We describe a 5-step approach for setting clinical performance specifications. The
approach and examples are summarised in Figure 1 and Table 1.

Step 1. Define the intended benefits
Researchers can start the process by bringing the findings of a biomarker discovery
study to relevant clinical groups to identify the target condition, the population for
testing and the intended benefits for patients or others. Ask ‘What patient or other
benefits do you hope to achieve by using the biomarker?’ We classify the potential
benefits of a new test into three broad categories that can be used as prompts: (1)
‘Will the test improve disease outcomes?’ e.g. by allowing more accurate or earlier
detection of the target condition that will benefit from treatment; (2) ‘Will the test
reduce iatrogenic harm?’ e.g. by offering more accurate, earlier or less invasive ruleout of the condition, so patients can avoid unnecessary further tests and treatment;
or (3) ‘Will the test provide other benefits?’ e.g. by improving patient or provider
12

experience such as the convenience of the testing process, or reduced costs,
without compromising accuracy.

Step 2. Map current practice
Defining the test purpose and desired changes in outcomes requires a close
understanding of the current clinical pathway. We recommend drawing a simple
flowchart of current practice with input from relevant clinician groups.19 This flowchart
should describe existing tests, if any; the key actions informed by the test results,
such as initiation, cessation or change of treatment or use of further tests; and the
health outcomes of these actions.

Step 3. Propose test role
Redraw the clinical pathway to show where the new test will be positioned to achieve
the intended benefits. Possible roles are as an add-on, triage or replacement test20;
or if no existing test, as a new test pathway. If intended to improve disease detection,
ask ‘Will the new test replace or be an add-on to the existing test(s)?’ If intended to
reduce the use of other tests or treatment, ask ‘Where will it be positioned in the
clinical pathway to allow triage of patients to avoid further testing and management?’
If intended to provide other benefits, ask ‘Is it intended to replace the existing test
without comprising accuracy?’

Step 4. Link clinical performance requirements to intended benefits
One can work back from the desired changes in outcomes to identify the clinical
performance requirements by asking ‘Will the intended benefits stem from detecting
13

more or earlier TP than the existing test? Or TN? Or from other test attributes without
compromising accuracy?’ For example, if the biomarker is intended to improve
disease outcomes by improving diagnosis and treatment, the intended benefits stem
from actions following a positive test result. Here, the new test strategy must
demonstrate more or earlier TP findings than the existing test strategy with an
acceptable number of FP. If intended to reduce harm by avoiding further testing and
treatment, the benefits stem from a negative test result. Here, the new test must
demonstrate more TN, or be positioned before the existing test strategy to allow
earlier rule out than existing tests with an acceptable number of FN. If proposed as a
replacement test with other benefits, the new test must demonstrate these benefits
with an acceptable number of FN and FP.

Step 5. Set minimum acceptable clinical performance levels
To set minimum acceptable clinical performance levels, ask ‘What harm–benefit
trade-off are you prepared to accept?’ Here, it is desirable to seek input from
clinicians, patients, policy-makers and other stakeholders.

Examples
1. Improve disease outcomes – FP:TP trade-off
For biomarkers intended to improve disease outcomes, the trade-off is between the
proposed benefit of TP and potential harm of undergoing unnecessary further tests
or treatment due to FP. To elicit the minimum acceptable trade-off, start by
describing the clinical consequences of a TP and a FP, then ask ‘What is the highest
number of individuals having a FP that you would be prepared to accept for one
14

additional individual to have the benefit of a TP finding?’ Apply this FP:TP threshold
to set the minimum acceptable PPV (PPV=TP/TP+FP). A test that does not meet
this threshold in test accuracy studies can be rejected from further evaluation.

An example is biomarkers for screening for ovarian cancer, where the intended
benefit of a TP is improved survival by detecting asymptomatic cancer at an early
stage when treatment is potentially more effective. The potential harm of a FP
includes unnecessary anxiety and further testing such as intravaginal ultrasound,
potentially leading to laparotomy to rule out cancer with the risk of surgical
complications. Using this information, if it is considered acceptable to detect one
cancer for every 50 women testing positive, i.e. 49 women receive a false alarm of
potential ovarian cancer and require further testing for each case of cancer detected
early (FP:TP=49:1); then the minimum acceptable PPV is 2%. Candidate biomarkers
such as CA-125 with a PPV below this value, can be rejected from further evaluation
as a population screening test. There is no need to set a minimum NPV if it is
reasonable to assume the consequences of a FN are not more harmful than no
screening.

Given current practice is no screening (TP=0), a biomarker with low sensitivity will
still warrant further evaluation if it meets the pre-specified FP:TP threshold. Pepe et
al. present worked examples to show how to calculate minimum acceptable
sensitivity and specificity combinations that meet the FP:TP threshold.12 This
calculation requires an estimate of the disease prevalence (Supplementary Figure).
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The FP:TP threshold will vary in different settings according to the consequences of
a FP. For ovarian cancer screening, others have set this threshold at 9:1 if a positive
test triggers a laparotomy, to arrive at a minimum PPV of 10%.21, 22

For tests achieving minimum clinical performance levels, further evaluation is
required to confirm claims of improved disease outcomes for TP. While threshold
setting presupposes there is some evidence that patients with the condition will
benefit from treatment or other actions such as counselling, this evidence is usually
for patients diagnosed with the condition using standard tests. It is pertinent to ask if
the additional TP identified by the new test will receive a treatment advantage for
(early) detection versus (delayed) diagnosis without the new test. For ovarian
screening tests, definitive evidence from clinical trials is still needed to confirm the
proposed treatment advantage from earlier detection. If the additional TP represent a
broader spectrum/definition of disease and would otherwise remain undetected
without the new test, the potential for overdiagnosis exists.23 Here, pertinent
questions for further evaluation are whether the additional cases are clinically
important or whether the harms of medical labelling and intervention outweigh any
benefits.

In these situations, clinical trials will be needed to provide definitive

evidence that the benefits of testing and subsequent actions outweigh the harms.

2. Reduce iatrogenic harm – FN:TN trade-off
For biomarkers intended to rule out disease, the test negativity rate indicates the
maximum proportion of patients who could benefit from rule-out to avoid
unnecessary further testing or treatment. The main potential for harm is a FN result.
16

Start by describing the clinical consequences of a TN and FN, then ask ‘How many
FN are you prepared to tolerate for every 100 (or 1000) patients ruled out?’ This
value can be used to set the minimum acceptable FN:TN threshold for patient safety
and the NPV (NPV=TN/TN+FN). Given all patients would receive further testing or
treatment under standard practice, a new test that meets the FN:TN threshold will
additionally be required to demonstrate a minimum acceptable sensitivity. This can
be set by asking ‘How many FN are you prepared to tolerate for every 100 patients
with the condition? One should check the frequency of FN under standard practice
without the new test when setting this value.

In the example of new tests to rule out acute coronary syndrome (ACS) in patients
presenting to the Emergency Department with chest pain, Than et al. reported on a
clinician survey to elicit the acceptable risk of FN.24 In this survey, the potential
consequences of a FN were described as a missed major adverse cardiac event
(MACE) within 30 days of discharge. Almost half the Emergency Department
clinician respondents considered up to 1 missed MACE per 100 patients to be
acceptable.24 These findings support a minimum acceptable NPV of at least 99%,
i.e. no more than 1 FN for every 100 patients eligible for discharge based on a
negative test result. The authors concluded that a new triage test should also be
required to demonstrate a minimum acceptable sensitivity of at least 99% - no more
than 1 missed diagnosis per 100 patients with ACS.

17

One should also consider the potential harms of a FP. These are generally less
consequential than a FN for rule-out tests; in particular if a positive result leads to
further testing, the same as would occur without the new test.

3. Other benefits – benchmark to existing tests
For biomarkers intended to provide other benefits without compromising accuracy,
minimum test accuracy levels can be benchmarked against the existing test. For
example, faecal immunochemical testing (FIT) was proposed to replace guaiac
faecal occult blood testing (FOBT) for screening to improve early detection of
colorectal cancer (TP) without increasing the rate of unnecessary colonoscopies
(FP).25 Here, minimum accuracy levels could be set to require sensitivity higher than
the existing guaiac test with non-inferior specificity. Alternatively, if the major
proposed benefit was greater adherence to testing due to no dietary restrictions,
then minimum sensitivity and specificity levels could be set at the same level as the
guaiac test. A study of adherence to testing would also be needed to provide
evidence of the intended benefits.

Another example is point-of-care D-dimer in primary care to replace laboratory
testing in low risk patients with suspected deep venous thrombosis, where the
intended benefit is improved patient and provider convenience.26 The clinical
sensitivity and specificity of the laboratory test provides a benchmark for point-ofcare tests. Here, the convenience of point-of-care testing may come at the expense
of analytical performance which can impact clinical accuracy. If a trade-off will be
tolerated between the proposed benefits of the test and the potential harms of more
18

FP or FN, benchmarking is not suitable; one can follow the approaches outlined
above to deal with this trade-off.

Benchmarking can also be used for new tests proposed for cost savings without
compromising accuracy. If the minimum clinical performance requirements are met,
then an economic analysis of the new test and all downstream costs versus current
practice would be needed to demonstrate the proposed benefits. If the cost savings
are proposed at the expense of clinical performance, benchmarking is not suitable.
Here, minimum clinical performance levels can be set by defining an acceptable
safety threshold for FN as described above for rule out tests.

The Supplementary Material outlines how the same approach can be used for tests
for other purposes beyond diagnosis and screening.

Discussion
We invite researchers to use this guide for setting minimum clinical performance
levels to strengthen clinical performance study design, interpretation and reporting.
By following this approach, researchers are pushed to seek information from clinical
groups, patients and other stakeholders about the potential consequences of test
results compared to current practice without the test, and judge the clinical benefits
versus harms that would support translation. The major advantage is to allow an
explicit and early determination of whether or not biomarker performance warrants
further evaluation as a medical test; and to reduce research waste and inappropriate
clinical use of poor performers.
19

We advocate setting the minimum clinical performance level to formulate a study
hypothesis that clinical performance is adequate for intended use. This is analogous
to setting the ‘minimum clinically important difference’ (the smallest change in an
outcome that a patient would identify as important) for a trial of a new treatment. One
should calculate the study sample size to provide adequate precision to test this
hypothesis; and include this information when reporting study results to meet the
STAndards for the Reporting of Diagnostic accuracy studies (STARD) guideline
requirements.8 A finding of test accuracy above the minimum acceptable level
supports the conclusion that clinical performance is sufficient for intended use.
Researchers can also use this guide when developing performance evaluation plans
to meet new EU regulations for IVDs.13

The decision-analytic principles for setting clinical performance specifications for
tests are well established.11, 12 In this paper, we focus on the practical aspects with
the aim to promote wider awareness and uptake of these methods among
laboratory, clinical and industry researchers. We provide a step-wise approach with
trigger questions to help guide collaboration between these groups. The importance
of early clinician input is shown by the example of high-sensitivity troponin as a triage
test for ACS assessment, which may have been rejected if safety concerns focused
on the frequency of FP rather than FN due to a poorly defined clinical pathway.

Where the clinical performance specifications are not met, laboratory professionals
can advise on the potential for further development to improve analytical
20

performance to meet these clinical needs. For illustration, we have presented
examples of single biomarker tests, however the principles also apply to biomarker
panels and multiplex "omics" as described by Skates et al.,27 where the need for
efficient screening of candidate biomarkers is very high.

For biomarkers with multiple potential indications, setting clinical performance
specifications for each indication may help prioritisation. For example, initial studies
demonstrating an association between procalcitonin and bacterial infection28
motivated wide clinical interest in its use to guide antibiotic decisions for a range of
indications. Regulatory approval followed, however in the critical care setting,
translation stalled despite accumulating evidence of test accuracy, with debate about
appropriate indications for use for patients with suspected or confirmed sepsis.29, 30
Setting a priori performance specifications for each potential indication (e.g. withhold
antibiotic therapy, stop antibiotic therapy early) to guide study design and
interpretation could help expedite definitive evaluation.

The trade-off between benefit and harm is a value judgement and can be expected
to vary among clinicians, patients and policy-makers. It may also vary between
healthcare settings due to considerations such as cost and clinical service capacity.
Researchers should therefore explain who participated in setting the minimum level
and how it was arrived at. The goal is not to reach a single point of agreement, but
rather to ensure the level set is transparent. If the value varies substantially between
groups, it can be set at a level low enough that most would agree a test not meeting
this level is not worth pursuing. While this is a basic approach to standard setting, we
21

argue it is less flawed than the typical approach of interpreting accuracy estimates
with no a-priori defined levels. As an extension, researchers can use the methods
described by Vickers et al. to plot a ‘decision curve’ of the net benefit of current
practice strategies (existing tests, no tests) across a plausible range of acceptable
FP:TP thresholds.18 The clinical performance specifications for a new biomarker to
improve on current practice can then be read from the plot at the threshold values of
interest to different individuals and groups.

Some trade-offs will be more challenging to deal with than those discussed here. For
example, where there are multiple important benefits and harms to weigh up or the
potential harms will be borne by patients but not the proposed benefits eg. cost
savings to the health system. In these situations, more complex approaches may be
needed, such as discrete choice experiments and multi-criteria decision-analytic
models.

Another challenge is that for some indications, it will not be possible to reach
agreement among clinicians about the current clinical pathway. The clinical pathway
will also vary between countries with different healthcare resources. A pragmatic
approach is to select the healthcare setting; patient group, existing tests and actions
most likely to favour the new test; and set the minimum performance levels for this
‘best case scenario’.

A potential criticism for adopting this approach in the early stages of biomarker
development is that directing evaluation toward a pre-defined clinical indication will
22

stifle innovation and preclude the discovery of broader biological insights. While
studies assessing the association between a biomarker and normal or pathological
processes are essential to advance knowledge of disease biology and identify
potential treatment targets; we argue that these need to be distinguished from
studies designed to develop and evaluate medical tests. Conflating these study
purposes is counter-productive and an important source of research waste, as
demonstrated by the extensive evaluation of cancer biomarkers, such as p5331
published in clinical journals, which are yet to find a role in routine clinical practice.

For tests meeting minimum clinical performance levels, validation in an independent
sample is still required. In some cases, this evidence will be sufficient for conclusions
about improved health outcomes. An example is FIT as a replacement for guaiacbased FOBT, where the clinical benefits of increased TP and TN are well
established. Where uncertainty exists, achieving minimum performance levels will be
necessary but not sufficient and randomised trials may be needed.32 In particular, for
tests proposed to improve disease outcomes, a randomised controlled trial will be
needed to demonstrate the effectiveness of management in patients with the
biomarker-defined condition who would have otherwise gone undetected using the
current test strategy. For definitive evidence about both benefits and harms, trials
comparing the new test strategy versus standard care with follow-up to assess
health outcomes are required, as have been performed for test strategies for ovarian
cancer screening33 and rule-out of ACS.34

23

Finally, the approach described demands early collaboration and crosstalk between
biomarker discovery researchers, clinicians, laboratory professionals, the IVD
industry, as well as patients and health policy makers. We hope this paper can help
facilitate these inter-professional discussions and lead to more efficient biomarker
translation to clinical practice.
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Table 1: Illustrative examples for setting clinical performance specifications
Steps

Purpose
‘New’ biomarker

Target
condition

1

Screening for
colorectal
cancer
Asymptomatic
Age ≥50 years

Point of care Ddimer

Diagnosis of
deep venous
thrombosis
Symptomatic

CA-125

Screening for
ovarian cancer
Asymptomatic
Age ≥50 years

High-sensitivity
troponin

Diagnosis of
Acute coronary

3

Intended benefits

Current
practice:
existing test

Improve disease
outcomes
by more accurate
early
detection and
treatment

Guaiac faecal
occult blood
test (FOBT)

Replacement

Other benefits
without
compromising
accuracy

Laboratorybased D-dimer

Replacement

Improve disease
outcomes
by early detection
and treatment

No testing

New test
pathway

Reduce harm
by earlier rule out to
avoid further testing/

Further
observation
and testing

Intended
population
Faecal
immunochemical
test

2

Test role

4
Clinical
performance
requirements

Approach

More TP
with acceptable FP

Benchmark to existing test accuracy:

Potential harm: More
FP leading to higher
colonoscopy rate

Triage
to rule out acute
coronary

5

Acceptable FP
Acceptable FN

Guaiac FOBT sensitivity, specificity
in a representative sample of
intended test population

Benchmark to existing test accuracy:
Laboratory-based D-dimer sensitivity,
specificity in representative sample of
intended test population

More TP
with acceptable FP

Define acceptable harm-benefit
trade-off*

Potential harm: FP
leading to
unnecessary further
testing +/laparoscopy

Calculate minimum PPV= TP/TP+FP
If up to 50 referrals for further testing
is acceptable to identify 1 TP,
tolerating 49 FP.
minimum PPV = 1/(1+49)
= 2%

Earlier TN
with acceptable FN
eg. risk of 30-day

25

Define acceptable risk of harm for
proposed benefits

syndrome
Symptomatic

admission

syndrome

major adverse
cardiac event

Calculate minimum NPV= TN/TN+FP
If up to 1 FN is acceptable for every
100 patients with ACS ruled out,
minimum NPV = 99/(99+1)
= 99%

FN=false negative; FP=false positive; NPV=negative predictive value; PPV=positive predictive value; TN=true negative; TP=true
positive
*See Supplementary Figure for worked example to calculate minimum acceptable sensitivity and specificity.

26

References
1.

Lumbreras B, Parker LA, Porta M, et al. Overinterpretation of clinical

applicability in molecular diagnostic research. Clin Chem. 2009; 55: 786-94.
2.

Parker LA, Chilet-Rosell E, Hernandez-Aguado I, et al. Diagnostic

Biomarkers: Are We Moving from Discovery to Clinical Application? Clin Chem.
2018; 64: 1657-67.
3.

Ochodo EA, de Haan MC, Reitsma JB, et al. Overinterpretation and

misreporting of diagnostic accuracy studies: evidence of "spin". Radiology. 2013;
267: 581-8.
4.

Hofmann B and Welch HG. New diagnostic tests: more harm than good. BMJ.

2017; 358: j3314.
5.

Diamandis EP. Cancer biomarkers: can we turn recent failures into success?

J Natl Cancer Inst. 2010; 102: 1462-7.
6.

Ioannidis JPA and Bossuyt PMM. Waste, Leaks, and Failures in the

Biomarker Pipeline. Clin Chem. 2017; 63: 963-72.
7.

Horvath AR, Lord SJ, StJohn A, et al. From biomarkers to medical tests: the

changing landscape of test evaluation. Clin Chim Acta. 2014; 427: 49-57.
8.

Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for

reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open.
2016; 6: e012799.
9.

Altman DG, McShane LM, Sauerbrei W et al. Reporting Recommendations for

Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS
Med. 2012; 9: e1001216.

27

10.

Friedman LM, Furberg CD, Demets DI, et al. Fundamentals of clinical trials,

5th Ed. 2015, Springer International Publishing; 2015.
11.

Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a

biomarker used for classification or prediction: standards for study design. J Natl
Cancer Inst. 2008; 100: 1432-8.
12.

Pepe MS, Janes H, Li CI, Bossuyt PM, et al.

Early-Phase Studies of

Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical
Utility? Clin Chem. 2016; 62: 737-42.
13.

Regulation (EU) 2017/746 of the European Parliament and of the Council of 5

April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC
and Commission Decision 2010/227/EU. http://eur-lex.Europa.Eu/eli/reg/2017/746/oj
(accessed November 2018).
14.

Study Group 5 of the Global Harmonization Task Force. Clinical evidence for

IVD medical devices — key definitions and concepts. GHTF/SG5/N6:2012.
http://www.Imdrf.org/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n6-2012-clinicalevidence-ivd-medical-devices-121102.Pdf (accessed November 2018).
15.

Leeflang MM, Rutjes AW, Reitsma JB, et al. Variation of a test's sensitivity

and specificity with disease prevalence. CMAJ. 2013; 185: E537-44.
16.

Usher-Smith JA, Sharp SJ and Griffin SJ. The spectrum effect in tests for risk

prediction, screening, and diagnosis. BMJ. 2016; 353: i3139.
17.

Vickers AJ and Elkin EB. Decision curve analysis: a novel method for

evaluating prediction models. Med Decis Making. 2006; 26: 565-74.

28

18.

Vickers AJ, Van Calster B and Steyerberg EW. Net benefit approaches to the

evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;
352: i6.
19.

Monaghan PJ, Lord SJ, St John A, et al. Biomarker development targeting

unmet clinical needs. Clin Chim Acta. 2016; 460: 211-9.
20.

Bossuyt PM, Irwig L, Craig J et al. Comparative accuracy: assessing new

tests against existing diagnostic pathways. BMJ. 2006; 332: 1089-92.
21.

Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European

Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005; 15:
679-91.
22.

Jacobs I and Bast RC, Jr. The CA 125 tumour-associated antigen: a review of

the literature. Hum Reprod. 1989; 4: 1-12.
23. Bell KJL, Doust J, Glasziou P, et al. Recognizing the Potential for Overdiagnosis:
Are High-Sensitivity Cardiac Troponin Assays an Example? Ann Intern Med. 2019;
170: 259-261.
24.

Than M, Herbert M, Flaws D, et al. What is an acceptable risk of major

adverse cardiac event in chest pain patients soon after discharge from the
Emergency Department?: a clinical survey. Int J Cardiol. 2013; 166: 752-4.
25.

Brenner H and Tao S. Superior diagnostic performance of faecal

immunochemical tests for haemoglobin in a head-to-head comparison with guaiac
based faecal occult blood test among 2235 participants of screening colonoscopy.
Eur J Cancer. 2013; 49: 3049-54.

29

26.

Geersing GJ, Toll DB, Janssen KJ, et al. Diagnostic accuracy and user-

friendliness of 5 point-of-care D-dimer tests for the exclusion of deep vein
thrombosis. Clin Chem. 2010; 56: 1758-66.
27.

Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen

cohort size in proteomics-based biomarker discovery and verification studies. J
Proteome Res. 2013; 12: 5383-94.
28.

Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin

concentrations in patients with sepsis and infection. Lancet. 1993; 341: 515-8.
29.

Moran JL, Solomon PJ. Procalcitonin as a biomarker for infection and sepsis:

Yet again. Pulm Crit Care Med. 2017; 2: 1-3.
30.

Afshari A and Harbarth S. Procalcitonin as diagnostic biomarker of sepsis.

Lancet Infect Dis. 2013; 13: 382-4.
31.

Hainaut P and Wiman KG. 30 years and a long way into p53 research. Lancet

Oncol. 2009; 10: 913-9.
32.

Lord SJ, Irwig L and Simes RJ. When is measuring sensitivity and specificity

sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann
Intern Med. 2006; 144: 850-5.
33.

Henderson JT, Webber EM and Sawaya GF. Screening for Ovarian Cancer:

Updated Evidence Report and Systematic Review for the US Preventive Services
Task Force. JAMA. 2018; 319: 595-606.
34.

Than MP, Pickering JW, Aldous SJ, et al. Effectiveness of EDACS Versus

ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized
Controlled Trial Embedded Within Practice. Ann Emerg Med. 2016; 68: 93-102.

30

